Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT: Dapagliflozin in Non-diabetic Stage IV CKD
NCT04794517Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Nov 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dapagliflozin in chronic kidney disease (CKD) (2 arms), sponsored by Mario Negri Institute for Pharmacological Research. Primary endpoints: Glomerular Filtration Rate at day 140 and 24-hour urinary protein excretion at day 126. Started Nov 2021; status: completed.
02
Drugs
dapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT04794517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794517.